Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

10 March, we concluded a consulting agreement on G-protein coupled receptor (GPCR) research with Professor Masashi Yanagisawa, an Investigator at the Howard Hughes Medical Institute, encompassing the purification and identification of orphan GPCR ligands, which are the unknown ligands, or molecules, bound to GPCRs. This agreement marks the launch of a full-scale GPCR program, the aim of which is to target GPCR in the discovery of neurological treatments. In the field of Alzheimer’s disease treatments—a field largely pioneered by Aricept— we signed an exclusive research agreement with Neurogentics Inc. for Alzheimer’s disease targets involving human genetics. In our second key therapeutic area, gastroenterology, the fast and consistent efficacy of the proton pump inhibitor Aciphex/Pariet, initially developed as a treatment of for a variety of gastrointestinal disorders, is contributing to its emergence as a major global drug. We are also stepping up efforts to develop additional indications for this important product. To date, Aciphex/Pariet has been granted regulatory approval as a treatment for gastroesophageal reflux disease (GERD) in Japan, the United States and the European Union (E.U.) and as a treatment for symtomatic GORD(GERD) in the E.U. We have filed for approval for Aciphex/Pariet for Helicobacter pylori eradication in the E.U., and have completed Phase III clinical trials for this indication in the United States. Also in the area of Helicobacter pylori eradication, we are conducting research on a new substance, E3309, a highly selective antimicrobial. We are continuing to strenthen our gastroentrology pipeline. Research in the area of cancer is carried out at the Tsukuba Research Laboratories and the Eisai Research Institute of Boston, which specializes in advanced synthetic organic chemistry and biological screening; and is particularly strong in the synthesis of natural bioactive compounds. Researchers at these facilities are Eisai Annual Report 2001
working together to develop anticancer agents and antiangiogenic drugs with favorable side effect profiles. In May 2001, we commenced Phase II clinical research of the sulfonamide deriviative E7070, a new type of anticancer agent. We are also developing E7389, an anticancer agent derived from naturally occurring substances, in collaboration with the U.S. National Cancer Institute. The Eisai Research Institute of Boston has developed E5564, a fully synthesized compound for treating sepsis. This substance, an endotoxin antagonist, has been developed to block the activities of bacterial endotoxins that play a key role in the development of sepsis. Substances under development in Japan include the rheumatoid arthritis treatment, T-614, genetically engineered tumor necrosis factor (TNF-α) antagonist D2E7 and the obesity management compound KES524 (sibutramine). Technology Platforms for Drug Discovery Bioinformatics* 1 plays an important role in genomics-based drug discovery. At Eisai, bioinformatics focuses on the construction of a database valuable for daily research activities and the development of proprietary software tools for data analysis. Our bioinformatics capabilities have been significantly reinforced via the agreement with Incyte Genomics Inc. in March 2001, which permits access to their proprietary cDNA (complementary DNA) database. Transcriptomics* 2 and proteomics* 3 , which are used for target validation and the functional analysis of genes, are also important technologies in genomics-based drug discovery. Utilizing these cutting edge technologies, together with genetics using model organisms— such as yeast and the nematode C. elegans—and knockout* 4 and transgenic* 5 technologies, we are conducting innovative genomicsbased drug discovery research. Eisai Annual Report 2001 * 1Bioinfomatics: Application of informatics in genomics, analyzing vast data sets of genome sequences and proteins for the discovery of target genes. * 2Transcriptomics: Analysis of gene expression profiles. * 3Proteomics: Analysis of whole protein expression. * 4Knockout technologies: Technology to produce model animals with defects in specific genes in order to analyze the function of the gene by observing the resulting phenotype. * 5Transgenic technologies: Technology to introduce foreign gene(s) into model animals, for analysis of the function of the gene and for construction of disease models. 11
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11: Selected Research Candidates (As of
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17 and 18: Consumer Health Care Products The c
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?